A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

Also called NCT02358096

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02358096
  • EudraCT 2014-002349-23
Other papers using this trial's data
  • Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial The lancet. Diabetes & endocrinology, 2018-12 DOI, PubMed 30413396

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02358096. Randomized; triple masking; primary purpose treatment. Start 2015-03-17 (actual); primary completion 2016-10-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
Acronym
ALBUM
Intervention (Drug)
ASP8232
Intervention (Drug)
Placebo
Lead sponsor
Astellas Pharma Europe B.V. (class: industry)

Record details

Record id
cardio:ct-nct02358096
Content hash
fe0d8b6e14aa407c569f35426714b3eb0f059255437e4219487baa1b2c172acd